HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Reviewing the Latest Bladder Cancer Practice Guidelines
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Chemotherapy Strategies for Metastatic PDAC
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Emerging Treatment Approaches for EBC
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.